Distribution of clinical Candida species and their susceptibility to antifungal agents

Basit Öğe Kaydı
dc.contributor.authorTumer, Seray
dc.contributor.authorBayraktar, Mehmet
dc.contributor.authorOzturk, Ali
dc.date.accessioned2024-11-07T13:32:06Z
dc.date.available2024-11-07T13:32:06Z
dc.date.issued2021
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractBackground: The incidence of fungal infections, especially by Candida species, has increased in recent years. This study was designed to isolate and identify Candida species from various clinical samples, and to examine their susceptibility to antifungal agents. Methods: A total of 175 Candida species were isolated from different clinical samples, and were identified using germ tube test, Cornmeal agar, and API C 20 AUX and VITEK 2 Compact Systems. Antifungal susceptibility of these isolates was determined using ATB Fungus 3 strip and VITEK 2 antifungal susceptibility cards. The results of these two methods were comparatively assessed. Results: A total of 175 Candida strains were isolated from 114 (65.1%) urine, 42 (24%) blood, eight (4.6%) sputum, seven (4%) endotracheal, and four (2.3%) wound samples. Of isolated Candida species, 102 (58.2%) were Candida albicans, 31 (17.6%) Candida tropicalis, 17 (9.6%) Candida parapsilosis, 13 (7.4%) Candida glabrata, three (1.8%) Candida kefyr, three (1.8%) Candida krusei, two (1.2%) Candida lusitaniae, and one (0.6%) Candida famata. By VITEK 2 antifungal susceptibility cards, the overall resistance rates were 0.6% to each of amphotericin B and 5-flucytosine, and 1.8% to fluconazole. In ATB Fungus 3 strip, the resistance (1.8%) was observed only to fulconazole. All isolates were uniformly susceptible to voriconazole in both methods. Conclusion: Valuable information and data on distribution and susceptibility of Candida strains were obtained. These data may be valuable from epidemiological point of view as well as for proper and optimal therapy of Candida infections in our region (Sanliurfa, Turkey). Copyright (C) 2021 Wolters Kluwer Health, Inc. All rights reserved.
dc.description.sponsorshipScientific Research Project Unit of Harran University, Turkey [2009/020-932]
dc.description.sponsorshipThe current study was funded by Scientific Research Project Unit of Harran University, Turkey (grant number; 2009/020-932).
dc.identifier.doi10.1097/MRM.0000000000000256
dc.identifier.endpage182
dc.identifier.issn0954-139X
dc.identifier.issn1473-5601
dc.identifier.issue3
dc.identifier.scopus2-s2.0-85122008179
dc.identifier.scopusqualityQ4
dc.identifier.startpage176
dc.identifier.urihttps://doi.org/10.1097/MRM.0000000000000256
dc.identifier.urihttps://hdl.handle.net/11480/15233
dc.identifier.volume32
dc.identifier.wosWOS:000668299000006
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofReviews in Medical Microbiology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241106
dc.subjectantifungal susceptibility
dc.subjectATB fungus
dc.subjectCandida albicans
dc.subjectnonalbicans Candida
dc.subjectVITEK 2 system
dc.titleDistribution of clinical Candida species and their susceptibility to antifungal agents
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu